Further assessing the duration, effect and ability to resist reinfection of anti-SARS-CoV-2 IgA, RBD Ab, and Nab antibodies in COVID-19 recovered patients is needed, and clarify the underlying mechanisms of their relationship. The gene discussed is CD79A; the disease is COVID-19.